Cerenome, Inc. (CNSY)
| Market Cap | 5.77M -92.5% |
| Revenue (ttm) | 4.20M -21.0% |
| Net Income | -26.09M |
| EPS | -4.37 |
| Shares Out | 7.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,723 |
| Open | 0.8054 |
| Previous Close | 0.8010 |
| Day's Range | 0.7600 - 0.8434 |
| 52-Week Range | 0.4287 - 18.8850 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 27.75 (+3,551.32%) |
| Earnings Date | Nov 13, 2026 |
About CNSY
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary li... [Read more]
Financial Performance
In 2025, Cerenome's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CNSY stock is "Strong Buy." The 12-month stock price target is $27.75, which is an increase of 3,551.32% from the latest price.
News
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today...
Cerenome appoints Ron Andrews as chief business officer
Cerenome (CNSY) announced the appointment of Ron Andrews as chief business officer, a newly created position. Andrews will continue to serve on the company’s board of directors. In his new…
Cerenome Appoints Director Ron Andrews as Chief Business Officer
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today...
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives
Cerenome completes enrollment in ReSPECT-GBM study
Cerenome (CNSY) announced that it has completed enrollment in the Phase 2 ReSPECT-GBM study. This multicenter, open-label trial is evaluating a single administration of Reyobiq, the company’s lead inv...
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Topline data expected in mid-2027 Previously reported interim Phase 2 data showed a 63% improvement in median overall survival versus standard of care in recurrent glioblastoma (13 months vs. 8 months...
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held...
Cerenome announces new dual mechanism of action for REYOBIQ
Cerenome (CNSY) announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ, its lead inv...
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeuti...
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.
Cerenome Launches CNSide® CSF Molecular Profile Tests
HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of t...
Cerenome Slides: Investor presentation
Cerenome has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Cerenome price target lowered to $31 from $50 at Lake Street
Lake Street lowered the firm’s price target on Cerenome (CNSY) to $31 from $50 and keeps a Buy rating on the shares. The firm’s revised price target reflects updated CNSide…
Cerenome Transcript: Investor update
CNSide achieved 158 million covered lives and began billing, with Medicare rates expected in early 2027. Test volumes and menu expansion are on track, and gross billings reached $1.55 million on 222 tests. Annualized run rate is projected at $10–12.5 million, with cash runway into 2028.
Cerenome Press release: Investor update
Cerenome issued a press release on September 30, 2026, disclosing material business information to investors.
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 202...
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced that management will h...
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an ...
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samant...
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028...
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, tar...
Cerenome Quarterly report: Q2 2026
Cerenome has published its Q2 2026 quarterly earnings report on August 14, 2026.
Cerenome Earnings release: Q2 2026
Cerenome released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-n...